Lead-Contaminated Vitamins

TLC provided daily multivitamin supplements to all participants as part of standard care. The supplements were intended to prevent mineral depletion during succimer treatment and to provide nutritional support.

In July 1997, routine quality testing revealed that a batch of supplements contained elevated lead levels. The contamination was traced to a manufacturing issue.

The fact that all but one trial site encouraged sharing supplements with siblings indicates a systematic practice that expanded the scope of exposure beyond trial participants.

The recall and investigation were reported in a separate 1999 publication in Pharmacoepidemiology and Drug Safety. Rogan et al. (1999) described the timeline and analysis:

• Contamination discovered: July 1997
• Immediate recall of affected batches
• Blood lead levels measured in 571 of 628 exposed participants
• Analysis of dose-response relationship between vitamin consumption and BLL

The investigators concluded that no dose-response effect was found between vitamin consumption and blood lead levels. Based on this analysis, they determined that no further action was needed.

The incident received minimal attention in the primary trial publications:

The primary NEJM paper (2001) states only: “One batch of vitamins was found to be contaminated with lead; an investigation showed that this had no effect on blood lead levels (see reference).”

The 7-year follow-up paper does not mention the incident at all, despite reporting on long-term cognitive outcomes.

The investigators analyzed whether the contaminated vitamins affected blood lead levels. They concluded no dose-response effect was found.

However, the impact on the primary outcome — IQ — was never analyzed. This is a significant gap:

• Even if BLL was not detectably elevated, transient lead exposure could have independent cognitive effects
• The incident occurred during a critical developmental window (ages 1–3 years)
• 81% of participants were potentially exposed, making this a trial-wide event
• A sensitivity analysis excluding exposed participants was never reported

Whether the contamination incident contributed to the null IQ finding cannot be determined from the published data. The lack of IQ analysis for this subgroup is inconsistent with the trial's focus on cognitive outcomes.

The vitamin contamination incident raises broader questions about trial quality assurance:

• How did contaminated supplements enter the supply chain?
• Why were all but one site encouraging sharing with siblings?
• Why was the IQ impact not analyzed, given it was the primary outcome?
• Why was the incident not mentioned in the 7-year follow-up?

While the incident likely had little effect on the overall trial result, the lack of rigor and candor in reporting and analysis raises questions about overall trial conduct. A trial testing cognitive outcomes in lead-exposed children should have carefully analyzed whether an incident exposing 81% of participants to additional lead affected those outcomes.